| Literature DB >> 34072736 |
Olubukola Sinbad Olorunnisola1, Peter Ifeoluwa Adegbola1, Bamidele Stephen Ajilore2, Olayemi Adebola Akintola3, Olumide Samuel Fadahunsi1.
Abstract
Consistent consumption of high salt diet (HSD) has been associated with increased cellular generation of free radicals, which has been implicated in the derangement of some vital organs and etiology of cardiovascular disorders. This study was designed to investigate the combined effect of some commonly employed medicinal plants on serum lipid profile and antioxidant status of aorta, kidney, and liver of high salt diet-fed animals. Out of the total fifty male Wistar rats obtained, fifteen were used for acute toxicity study, while the remaining thirty-five were divided into 5 groups of 7 animals each. Group 1 and 2 animals were fed normal rat chow (NRC) and 16% high salt diet (HSD) only, respectively. Animals in groups 3, 4 and 5 were fed 16% HSD with 800, 400, and 200 mg/kg bw poly-herbal extract (PHE), respectively, once for 28 consecutive days. Serum low-density lipoprotein (LDL), triacylglycerol (TG), total cholesterol (TC) and high-density lipoprotein (HDL), malondialdehyde, nitric oxide, catalase, superoxide dismutase, glutathione peroxidase, glutathione concentration, and activities were assessed in the aorta, kidney, and liver. Poly-herbal extract (p < 0.05) significantly reduced malondialdehyde and nitric oxide concentrations and also increased antioxidant enzymes and glutathione activity. Elevated serum TG, TC, LDL, and TC content in HSD-fed animals were significantly (p < 0.05) reduced to normal in PHE-treated rats while HDL was significantly elevated (p < 0.05) in a concentration-dependent manner in PHE treated animals. Feeding with PHE attenuated high-salt diet imposed derangement in serum lipid profile and antioxidant status in the organs of the experimental rats.Entities:
Keywords: antioxidants; aorta; kidney; lipid profile; liver; poly-herbal; sodium chloride
Year: 2021 PMID: 34072736 PMCID: PMC8228643 DOI: 10.3390/medicines8060025
Source DB: PubMed Journal: Medicines (Basel) ISSN: 2305-6320
Animal grouping and experimental design.
| Groups | Treatment |
|---|---|
| 1 | Fed with normal rat chow only (positive control) |
| 2 | Fed with 16% salt diet only (negative control) |
| 3 | Fed with 16% salt diet and 800 mg/kg of the poly-herbal extract once daily |
| 4 | Fed with 16% salt diet and 400 mg/kg of the poly-herbal extract once daily |
| 5 | Fed with 16% salt diet and 200 mg/kg of the poly-herbal extract once daily |
Figure 1(a) Malondialdehyde (MDA) and Nitric oxide (NO) concentration in the liver of rats. (b) Super oxide dismutase (SOD) and catalase (CAT) activity in the liver of rats. Data were expressed as mean ± SEM. Bar charts with different alphabets are significantly (p < 0.05) different. NRC: normal rat chow; HSD: high salt diet; PHE: poly-herbal extract. Figure 1b revealed that SOD and CAT activities were reduced in the liver of the high salt fed (HSD) rats and were significantly (p < 0.05) increased after treatment with 800 and 400 mg/kg poly-herbal extract (PHE).
Concentration of GSH, GPx, and GST in the liver of rats.
| Treatment | GSH (µmol/g) | GPX (µmol/g) | GST (µmol/g) |
|---|---|---|---|
| NRC | 2.77 ± 0.30 ab | 0.63 ± 0.04 bc | 5.90 ± 0.91 b |
| HSD only | 2.29 ± 0.44 ab | 0.55 ± 0.01 ab | 3.34 ± 0.54 a |
| HSD + 800 mg/kg PHE | 3.25 ± 0.38 b | 0.81 ± 0.07 d | 6.37 ± 0.81 b |
| HSD + 400 mg/kg PHE | 2.67 ± 0.08 ab | 0.73 ± 0.01 cd | 5.66 ± 0.55 b |
| HSD + 200 mg/kg PHE | 2.04 ± 0.23 a | 0.42 ± 0.05 a | 4.34 ± 0.54 ab |
Data were expressed as mean ± SEM. Values with different superscripts down the column are significantly different (p < 0.05). NRC: normal rat chow; HSD: high salt diet; PHE: poly-herbal extract.
Figure 2(a) Malondialdehyde (MDA) and Nitric oxide (NO) concentration in the liver of rats. (b) Catalase activity in the kidney of rats. Bar charts with different alphabets are significantly (p < 0.05) different. NRC, normal rat chow; HSD, high salt diet; PHE: poly-herbal extract. The concentration of GSH and activities of GPx and GST were significantly (p < 0.05) reduced in the kidneys of HSD only fed rats Table 3. However, treatment with 800 and 400 mg/kg PHE significantly (p < 0.05) elevated the activities of these proteins.
Concentration of GSH, GPx, and GST in the kidney of rats.
| Treatment | GSH (µmol/g) | GPX (µmol/g) | GST (µmol/g) |
|---|---|---|---|
| NRC only | 1.61 ± 0.25 bc | 0.55 ± 0.02 b | 2.41 ± 0.39 b |
| HSD only | 0.91 ± 0.04 a | 0.31 ± 0.04 a | 0.50 ± 0.13 a |
| HSD + 800 mg/kg PHE | 1.68 ± 0.15 bc | 1.09 ± 0.03 d | 2.41 ± 0.39 b |
| HSD + 400 mg/kg PHE | 1.50 ± 0.16 bc | 0.76 ± 0.05 c | 1.39 ± 0.13 ab |
| HSD + 200 mg/kg PHE | 1.09 ± 0.02 ab | 0.76 ± 0.06 c | 0.50 ± 0.01 a |
Data were expressed as mean ± SEM. Values with different superscripts down the column are significantly different (p < 0.05). NRC: normal rat chow; HSD: high salt diet; PHE: poly-herbal extract.
Figure 3(a) MDA and NO activities in the aorta of rats. (b) SOD and CAT activities in the aorta of rats. Bar charts with different alphabets are significantly (p < 0.05) different. NRC, normal rat chow; HSD, high salt diet; PHE: poly-herbal extract.
GSH, GPx, and GST activities in the aorta of rats.
| Treatment | GSH (µmol/g) | GPX (µmol/g) | GST (µmol/g) |
|---|---|---|---|
| NRC only | 2.77 ± 0.3 ab | 0.63 ± 0.04 b | 5.90 ± 0.91 b |
| HSD only | 1.93 ± 0.25 a | 0.51 ± 0.03 a | 3.34 ± 0.54 a |
| HSD + 800 mg/kg PHE | 3.25 ± 0.38 b | 0.71 ± 0.04 b | 6.37 ± 0.81 b |
| HSD + 400 mg/kg PHE | 2.67 ± 0.08 ab | 0.66 ± 0.05 b | 5.61 ± 0.55 b |
| HSD + 200 mg/kg PHE | 2.03 ± 0.23 a | 0.68 ± 0.04 b | 4.34 ± 0.54 ab |
Data were expressed as mean ± SEM. Values with different superscripts down the column are significantly different (p < 0.05). NRC: normal rat chow; HSD: high salt diet; PHE: poly-herbal extract.
Concentration of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) in the serum of rats.
| Treatment | HDL (mg/dL) | LDL (mg/dL) |
|---|---|---|
| NRC only | 6.63 ± 0.43 ab | 35.06 ± 1.97 c |
| HSD only | 4.91 ± 0.85 a | 163.29 ± 1.59 f |
| HSD + 800 mg/kg PHE | 22.83 ± 0.72 d | 9.67 ± 1.67 a |
| HSD + 400 mg/kg PHE | 21.99 ± 0.64 d | 27.25 ± 2.69 b |
| HSD + 200 mg/kg PHE | 12.09 ± 1.20 c | 89.30 ± 3.76 e |
NRC: normal rat chow; HSD: high salt diet; PHE: poly-herbal extract. Values with different superscripts down the column are significantly different (p < 0.05). NRC: normal rat chow; HSD: high salt diet; PHE: poly-herbal extract.
Figure 4Serum triacylglycerol and cholesterol concentration in the serum of rats. Data were expressed as mean ± SEM. Bar charts with different alphabets are significantly different (p < 0.05).
Figure 5GC–MS chromatogram of the investigated poly-herbal extract.
Compounds detected in the poly-herbal extract using GC–MS analysis.
| Retention Time | Identified Compounds | Peak Area % | |
|---|---|---|---|
| 1 | 2.651 | Arsenous acid, tris(trimethylsilyl)ester | 0.09 |
| 2 | 2.905 | 2,4-Cyclohexadien-1-one | 0.07 |
| 3 | 3.271 | Cyclotrisiloxane, hexamethyl- | 0.21 |
| 4 | 3.834 | 1,4-Bis(trimethylsilyl)benzene | 1.18 |
| 5 | 4.341 | Tris(tert-butyldimethylsilyloxy)arsane | 0.05 |
| 6 | 4.398 | 1,1,1,3,5,5,5-Heptamethyltrisiloxane | 0.06 |
| 7 | 4.764 | 4-Methyl-2-trimethylsilyloxy-acetophenone | 0.13 |
| 8 | 4.905 | 1,3,5,7-Cyclooctatetraene | 0.39 |
| 9 | 5.327 | Cyclotetrasiloxane, octamethyl- | 0.14 |
| 10 | 5.440 | Trans-4-Dimethylamino-4’-methoxych alcone | 0.39 |
| 11 | 5.834 | 1,1,3,3,5,5,7,7-Octamethyl-7-(2-methylpropoxy) tetrasiloxan-1-ol | 0.26 |
| 17 | 6.961 | 1,1,1,3,5,5,5Heptamethyltrisiloxane | 0.05 |
| 18 | 7.158 | Arsenous acid, tris(trimethylsilyl) ester | 0.04 |
| 19 | 7.468 | 1,2-Bis(trimethylsilyl)benzene | 0.11 |
| 20 | 7.722 | 1,1,1,3,5,5,5Heptamethyltrisiloxane | 0.04 |
| 22 | 8.510 | Cyclopentasiloxane, decamethyl- | 1.22 |
| 23 | 8.736 | 5-Methyl-2-phenylindolizine | 0.12 |
| 24 | 9.017 | 3,3-Diisopropoxy-1,1,1,5,5,5-hexam ethyltrisiloxane. | 0.05 |
| 25 | 9.186 | 1,2,4Triazolo[1,5-a]pyrimidine-6-carboxylic acid | 0.04 |
| 26 | 9.327 | Silane | 0.10 |
| 27 | 9.863 | Octasiloxane, 1,1,3,3,5,5,7,7,9,9, | 0.23 |
| 28 | 10.144 | 4-Bromo-3-chloroaniline | 0.32 |
| 29 | 10.285 | Cyclohexasiloxane, dodecamethyl- | 1.47 |
| 30 | 10.651 | Heptasiloxane, 1,1,3,3,5,5,7,7,9,9,11,11,13,13-tetradecamethyl- | 0.54 |
| 31 | 10.961 | Alpha.-D-Ribofuranoside ((2-pyridy l)-2,3-O-isopropylidene-1-thio- | 1.28 |
| 32 | 11.384 | Coumarin | 1.01 |
| 33 | 11.609 | Cycloheptasiloxane, tetradecamethy1- | 1.85 |
| 34 | 11.947 | Anthracene, 9,10-diethyl-9,10-dihydro- | 0.38 |
| 35 | 12.313 | 3-Quinolinecarboxylic acid, 6,8-di fluoro-4-hydroxy-, ethyl ester | 1.15 |
| 36 | 12.595 | 2-Ethylacridine | 0.74 |
| 37 | 12.680 | Cyclooctasiloxane, hexadecamethyl- | 1.02 |
| 38 | 12.792 | 5,5’-Di(ethoxycarbonyl)-3,3’-dimethyl-4,4’-dipropyl-2,2’-dipyrrylmethane | 0.97 |
| 39 | 13.018 | Trans-3-Ethoxy-b-methyl-b-nitrostyrene | 1.58 |
| 40 | 13.187 | Corydaldine | 1.11 |
| 41 | 13.356 | Benzene, 1,1’-(1,2-cyclobutanediyl)bis-,trans- | 5.15 |
| 42 | 13.778 | Isopulegol | 1.78 |
| 43 | 13.947 | Bicyclo[4.1.0]hepta-2,4-diene, 2,3,4,5-tetraethyl-7,7-diphenyl- | 2.93 |
| 44 | 14.144 | 2-Methyl-7-phenylindole | 2.10 |
| 45 | 14.398 | 1H-Indole-2-carboxylic acid, 6-(4- ethoxyphenyl)-3-methyl-4-oxo-4,5,6,7-tetrahydro-, isopropyl ester | 4.10 |
| 46 | 14.539 | Scopoletin | 3.66 |
| 47 | 14.680 | Bicyclo[3.3.1]nonan-2-one,1-methyl-9-(1-methylethylidene)- | 2.45 |
| 48 | 14.933 | 2,4,6-Trimethylphenyl isothiocyanate | 1.79 |
| 49 | 15.074 | Deoxyqinghaosu | 8.46 |
| 50 | 15.271 | N-(2-Acetylcyclopentylidene)cyclohexylamine | 4.18 |
| 51 | 15.412 | Fluorenoneoxime | 2.58 |
| 52 | 15.750 | 6-Methoxy-2-hydroxyquinoxaline-4-oxide | 2.80 |
| 53 | 15.947 | Benzo[h]quinoline, 2,4-dimethyl- | 1.51 |
| 54 | 16.088 | Tris(tert-butyldimethylsilyloxy)arsane | 1.87 |
| 55 | 16.257 | 9,10-Anthraquinone monohydrazone | 3.83 |
| 56 | 16.426 | 1,2-Benzisothiazol-3-amine tms | 2.02 |
| 57 | 17.215 | Benzene, 2-[(tert-butyldimethylsil yl)oxy]-1-isopropyl-4-methyl- | 8.83 |
| 58 | 17.863 | 1,2-Bis(trimethylsilyl)benzene | 2.10 |
| 59 | 18.229 | Tetrasiloxane, decamethyl- | 1.49 |
| 60 | 18.595 | 2,3-Diphenylcyclopropyl)methylphenylsulfoxide, trans- | 3.59 |
| 61 | 18.764 | Trimethyl[4-(2-methyl-4-oxo-2-pent yl)phenoxy]silane | 0.62 |